Discontinued — last reported Q2 '23
Over 2 years (FY 2021 to FY 2023), Acquisitions shows a downward trend with a -100.0% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $469.00M | $0.00 | $2.29B | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $122.00M |
| QoQ Change | — | -100.0% | — | -100.0% | — | — | — | — | — | — | — | — | — |
| YoY Change | — | — | — | — | -100.0% | — | -100.0% | — | — | — | — | — | — |